Trinity Biotech (TRIB) Payables (2009 - 2025)

Trinity Biotech has disclosed Payables across 17 years of filings, most recently posting $29.7 million for Q4 2025.

• Payables for Q4 2025 came in at $29.7 million, up 10.91% year-over-year; the trailing twelve-month figure through Dec 2025 was $29.7 million (up 10.91% YoY), and the FY2025 annual result was $29.7 million, up 10.91% from the prior year.
• Payables came in at $29.7 million for Q4 2025 at Trinity Biotech, up from $26.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $98.4 million in Q4 2021 to a low of $12.2 million in Q3 2023.
• The 5-year median for Payables is $19.4 million (2021), against an average of $23.9 million.
• Across the five-year window, Payables surged 304.52% in 2021 and slumped 84.38% in 2022, its largest moves.
• Trinity Biotech's Payables stood at $98.4 million in 2021, then plunged by 84.38% to $15.4 million in 2022, then dropped by 16.73% to $12.8 million in 2023, then jumped by 109.2% to $26.8 million in 2024, then grew by 10.91% to $29.7 million in 2025.
• The last three Payables figures came in at $29.7 million (Q4 2025), $26.5 million (Q2 2025), and $26.8 million (Q4 2024), per Business Quant data.